Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT04307615
Recruiting Not applicable

O2 Versus CPAP Treatment Of Patients Undergoing SIPE Therapy (OCTOPUS)

NCT04307615 · tracked via the Priya Life Science Sweden tracker
Sponsor
Dalarna County Council, Sweden
Phase
Not applicable
Started
2022-07-02
Last updated
2026-10-05

Condition(s) studied

Swimming Induced Pulmonary Edema (SIPE)Pulmonary EdemaLung Diseases

Investigational drug(s) / intervention(s)

Oxygen + continuous positive airway pressure (CPAP)Oxygen

Oxygen + continuous positive airway pressure (CPAP): Oxygen-driven CPAP (7,5 cmH2O): 20 min treatment followed by 10 min rest and assessment

Oxygen: Oxygen: 20 min treatment followed by 10 min rest and assessment

Study summary

In swimming induced pulmonary edema (SIPE), there is a lack of knowledge regarding optimal treatment. The present study was designed to assess the benefit of continuous positive airway pressure (CPAP) compared to oxygen as a first line treatment of SIPE in the out-of-hospital environment.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * clinical diagnosis of swimming induced pulmonary edema (SIPE) with need of acute treatment (oxygen saturation ≤91%) * 18 years and older * informed consent Exclusion Criteria: * declined consent * suspected acute coronary syndrome * severe asthma diagnosed together with pulmonary edema where beta-agonist-inhalation is needed prior to treatment of pulmonary edema * hemodynamic instability or decreased consciousness

Primary outcome measure(s)

  • Absolute peripheral oxygen saturation (%) after treatment — after 20 min treatment followed by 10 min rest
    Peripheral oxygen saturation % (continuous variable) measured by peripheral pulse oximetry

Trial sites (1)

FacilityCityRegionStatus
Center of Clinical Research Dalarna Falun Sweden Recruiting

More Dalarna County Council, Sweden trials in Sweden

Bowel And Bladder Function in Infant Toilet Training Active, not recruiting
Oral Cancer Screening for Early Detection of Premalignant Disorders (PMOD) Recruiting
Effects of Negative Pressure Wound Bandaging After Mastectomy Recruiting
Stability of Hand Grip Strength Across a Competitive Season in Elite Male and Female Ice Hockey Players Starting soon
PEP-device for Treatment of Swimming-induced Pulmonary Edema (SIPE) Recruiting

Other trials for the same condition

PEP-device for Treatment of Swimming-induced Pulmonary Edema (SIPE) Recruiting
Swedish CArdioPulmonary bioImage Study 2 Recruiting
Cardiac Function in Swimming-Induced Pulmonary Edema (SIPE) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04307615 on ClinicalTrials.gov ↗ ← All trials in Sweden